--- title: "Upstream Bio (UPB) news: offering" url: "https://aibio.space/companies/upstream-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "UPB offering news: Upstream Bio sets up $150,000,000 at-the-market stock program with Leerink. Upstream Bio, Inc. (NASDAQ: UPB), United States." --- UPB Upstream Bio, Inc. NASDAQ · United States # Upstream Bio (UPB) news UPB offering news Financings · 2026-03-26 ## [Upstream Bio sets up $150,000,000 at-the-market stock program with Leerink](https://aibio.space/news/upstream-bio-sets-up-150-000-000-market-stock-program-leerink/) Upstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025. ## Latest Upstream Bio news We have not published a story on Upstream Bio yet. When there is news, it will appear here. ## Upstream Bio at a glance - **Ticker**: UPB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $261.3 million ### Related companies - [Range Impact](https://aibio.space/companies/range-impact/) OTC: RNGE - [Bright Minds Biosciences](https://aibio.space/companies/bright-minds-biosciences/) CSE: DRUG - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) NASDAQ: LYEL - [XBiotech](https://aibio.space/companies/xbiotech/) NASDAQ: XBIT - [Tango Therapeutics](https://aibio.space/companies/tango-therapeutics/) NASDAQ: TNGX - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) NASDAQ: SRRK ### Also on NASDAQ - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) SPTX - [Traws Pharma](https://aibio.space/companies/traws-pharma/) TRAW - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) ERNA - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [ProKidney](https://aibio.space/companies/prokidney/) PROK - [Passage Bio](https://aibio.space/companies/passage-bio/) PASG ## What Upstream Bio does Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Its candidate, verekitug, is a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor. The company describes verekitug as the only known antagonist of the TSLP receptor currently in clinical development. Upstream reported positive top-line results in its Phase 2 chronic rhinosinusitis with nasal polyps (CRSwNP) trial in September 2025 and in its Phase 2 severe asthma trial in February 2026. A Phase 2 trial in chronic obstructive pulmonary disease (COPD) began in July 2025. The company plans to start Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027, with quarterly at-home administration. Three Phase 1 trials have been completed for verekitug across a total of 120 participants. The filing compares verekitug with tezepelumab, a TSLP ligand antibody marketed by Amgen and AstraZeneca, and states that no head-to-head clinical studies against tezepelumab have been conducted. Upstream also says it intends to develop verekitug for other TSLP-driven diseases. | Product or program | What it is | Stage | |---|---|---| | Verekitug | TSLP receptor monoclonal antibody for severe asthma, CRSwNP and COPD | Phase 2 | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/upb-20251231.htm). ## Upstream Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.9 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | | Research and development | [$136.8 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | [$63.0 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | | Net income (loss) | [-$143.4 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | [-$62.8 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | | Cash from operations | [-$133.3 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | [-$59.2 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | | Cash and equivalents | [$101.6 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526343417/) | [$325.9 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | | Short-term investments | [$239.9 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526343417/) | [$144.6 million](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126188/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $79.4 million, plus short-term investments of $181.9 million, $261.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Upstream Bio Has Upstream Bio raised money recently? Our latest story on this, dated Mar 26, 2026: "Upstream Bio sets up $150,000,000 at-the-market stock program with Leerink". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/upstream-bio-sets-up-150-000-000-market-stock-program-leerink/). What is the ticker symbol of Upstream Bio? Upstream Bio, Inc. trades under the ticker UPB on NASDAQ. Where is Upstream Bio listed? Upstream Bio, Inc. is listed on NASDAQ. What is the SEC CIK of Upstream Bio? The SEC Central Index Key (CIK) for Upstream Bio, Inc. is 2022626. Its filings are on SEC EDGAR. How many shares does Upstream Bio have outstanding? 54,771,041 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Upstream Bio listed under? Our directory records Upstream Bio, Inc. under United States. What does Upstream Bio do? Our directory classifies Upstream Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Upstream Bio? The ISIN recorded for Upstream Bio, Inc. is US91678A1079. Does aibio.space cover Upstream Bio? aibio.space lists Upstream Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Upstream Bio incorporated? SEC records list its state or country of incorporation as DE. What does Upstream Bio develop? Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Its candidate, verekitug, is a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor. What is Verekitug from Upstream Bio? Verekitug: TSLP receptor monoclonal antibody for severe asthma, CRSwNP and COPD Stage: Phase 2. What was Upstream Bio's revenue last year? $2.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Upstream Bio profitable? Upstream Bio, Inc. reported a net loss of $143.4 million for the fiscal year ended Dec 31, 2025, and used $133.3 million of cash in operations, per its annual report to the SEC. How much does Upstream Bio spend on research and development? $136.8 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Upstream Bio Members talk about Upstream Bio (UPB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Upstream Bio, newest first. Each line links the filing it comes from. 1. 2026-03-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126561/d126101d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:UPB on TradingView](https://www.tradingview.com/symbols/NASDAQ-UPB/). ## SEC filings and registration - **SEC name**: Upstream Bio, Inc. - **CIK**: 2022626 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: UPB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451 - **Phone**: 781-208-2466 - **Shares outstanding**: 54,771,041 as of 2026-08-04 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526377485/upb-20260901.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/2022626/000119312526343417/upb-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526265800/upb-20260609.htm) filed 2026-06-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/2022626/000119312526220584/upb-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526220578/upb-20260513.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2022626/000119312526158966/upb-20260416.htm) filed 2026-04-16 - [8-K](https://www.sec.gov/Archives/edgar/data/2022626/000119312526126572/d110609d8k.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002022626), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Upstream Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker UPB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Upstream Bio, Inc. - **Ticker**: UPB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US91678A1079 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-UPB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/upstream-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Upstream Bio (UPB) news: offering", 2026-10-31, https://aibio.space/companies/upstream-bio/